HA
Therapeutic Areas
Day One Biopharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| OJEMDA™ (tovorafenib) | Pediatric Low-Grade Glioma (pLGG) | Approved |
| Emi-Le (XMT-2056) | HER2-positive Solid Tumors | Phase 1 |
| XMT-1660 | Solid Tumors (B7-H4 targeting) | Phase 1 |
| XMT-2315 | Solid Tumors (NaPi2b targeting) | Phase 1 |
| Tovorafenib (DAY101) | Adult Solid Tumors | Phase 1/2 |